Axonics Stockholders Approve Merger Agreement With Boston Scientific; Expected To Occur In The First Half Of 2024 And Remains Subject To Certain Conditions
Axonics Stockholders Approve Merger Agreement With Boston Scientific; Expected To Occur In The First Half Of 2024 And Remains Subject To Certain Conditions
Axonics, Inc. (NASDAQ:AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE:BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics' common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independent inspector of election, will be reported on a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
Axonics, Inc.（納斯達克股票代碼：AXNX）宣佈，其股東今天投票通過了Axonics與波士頓科學公司（紐約證券交易所代碼：BSX）的合併協議。根據今天早些時候舉行的股東特別會議的初步投票結果，Axonics已發行並有權在特別會議上投票的大多數普通股都投票贊成通過合併協議。由獨立選舉檢查員列出的最終投票結果將在向美國證券交易委員會提交的8-K表格中報告。
"We want to thank Axonics' stockholders for their strong support of our transaction with Boston Scientific," said Raymond W. Cohen, chief executive officer of Axonics. "Our team is looking forward to the global impact we can make as part of Boston Scientific as we endeavor to bring our life-changing therapies to more patients than ever before."
Axonics首席執行官雷蒙德·科恩表示：“我們要感謝Axonics的股東對我們與波士頓科學交易的大力支持。”“我們的團隊期待作爲波士頓科學的一員，在努力將改變生活的療法帶給比以往任何時候都更多的患者時，我們能夠產生全球影響。”
The closing of the transaction is expected to occur in the first half of 2024 and remains subject to certain conditions, including receipt of approvals or clearances, or the expiration, termination or waiver of applicable waiting periods under U.S. and foreign antitrust laws.
該交易預計將於2024年上半年完成，但仍受某些條件的約束，包括獲得批准或許可，或者美國和外國反壟斷法規定的適用等待期的到期、終止或豁免。
譯文內容由第三人軟體翻譯。